No abstract available
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Anticoagulants / therapeutic use
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Biomarkers
-
COVID-19
-
COVID-19 Drug Treatment
-
COVID-19 Vaccines
-
Clinical Trials as Topic / standards*
-
Community Participation
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / immunology
-
Coronavirus Infections / prevention & control
-
Drug Approval*
-
Drug Evaluation
-
Drug Industry
-
Humans
-
Immunomodulation
-
International Cooperation
-
Pandemics / prevention & control
-
Plasma
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / prevention & control
-
Time Factors
-
United States
-
United States Food and Drug Administration
-
Viral Load / drug effects
-
Viral Vaccines
Substances
-
Antibodies, Monoclonal
-
Anticoagulants
-
Antiviral Agents
-
Biomarkers
-
COVID-19 Vaccines
-
Viral Vaccines